Investing.com - Coherus BioSciences (NASDAQ: CHRS) reported third quarter EPS of $-0.010, $0.15 better than the analyst estimate of $-0.160. Revenue for the quarter came in at $70.77M versus the consensus estimate of $58.98M.
Coherus BioSciences's stock price closed at $0.72. It is down -49.370% in the last 3 months and down -70.690% in the last 12 months.
Coherus BioSciences saw 1 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Coherus BioSciences's stock price’s past reactions to earnings here.
According to InvestingPro, Coherus BioSciences's Financial Health score is "fair performance".
Check out Coherus BioSciences's recent earnings performance, and Coherus BioSciences's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar